AZ Secures EU Fast-Tack Review For Nirsevimab
First Filing Worldwide Submitted To EMA For Novel Anti-RSV Immunization For All Infants
There could be a regulatory decision on AstraZeneca and Sanofi's nirsevimab in the EU in H2 as a result of the European Medicines Agency speeding up its review of the marketing application for the potential new immunization against RSV in all infants.
